Compass Pathways reports 1-year Phase 3 COMP005 results
Sponsored ADR (NASDAQ:CMPS) says its Phase 3 COMP005 Part C showed a 1-year mean 13-point MADRS drop with 40–45% ≥50% response and ~30% remission, and safety consistent with prior phases; it will present HEOR TRD/MDD real-world cost posters.